Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

FreeStyle Libre 2 (adults and children 4 years and older) FreeStyle Libre 3 (adults and children 4 years and older) Similar ...

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

Thursday, Abbott Laboratories ABT said it is recalling some FreeStyle Libre 3 sensors after finding ... Continuous Glucose Monitoring To Type 2 Diabetes Patients. This recall involves removing ...

Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 million diabetes patients by offering continuous glucose monitoring with ...

Abbott’s FreeStyle Libre products have more than six million users who have type 1 or type 2 diabetes. She added that the collaboration provides people with diabetes expanded choice, calling it ...

The Food and Drug Administration cleared Abbott’s Freestyle Libre 2 and 3 for integration with AID systems in March 2023. Earlier this year, Abbott integrated its FreeStyle Libre 2 Plus sensor with ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Among the many corporations that pay a dividend, some do so unpredictably and irregularly. Others rarely raise their payouts ...